November 2004
Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30        
Oct   Dec


For more search options, please see the Advanced search form and the section of the User's Guide, Tips for Searching PULSE.


C H A N N E L S
• PULSE Home Page
• EXECUTIVE EDITION

• US News
• Canada News
• UK News
• New Zealand News

• Consumer Advocacy
• Health Care Systems
• Managed Care/Medicaid
• Co-occurring Disorders
• Clinical studies
• Pharmaceutical News
• Criminal Justice Systems
• Legislative News


U S E R ' S   G U I D E
About PULSE
PULSE Channels
Archives
Adding comments
Using the # link
Items that require registration
PULSE syndication
Tips for Searching PULSE


E M A I L   S U B S C R I P T I O N S

For WEEKLY summaries of PULSE postings, see the weekly email subscription form.

For DAILY mailings (powered by Bloglet), please enter your e-mail address below:


P U B L I C A T I O N S

PULSE ANNUAL No. 2
January 2003

Recent Trends, Challenges and Issues in Funding Public Mental Health Services in the US
March 2002

PULSE ANNUAL No. 1
October 2001

 

PULSE is powered by
Radio Userland.

Listed on BlogShares

© Bill Davis, 2000-2003.

About PULSE | Channels | User's Guide | Email subscriptions | Publications




PULSE is a free service of the Centre for Community Change International, gathering new and noteworthy Internet resources for mental health providers, family members of individuals with mental illness, consumers of mental health services and consumer advocates. PULSE is researched, edited and designed by Bill Davis.



daily link  Monday, November 15, 2004


New Antidepressant Drug Approved, But It's All About Profits, Not Helping Patients
Commentary column at DepressionFactor.org - "The FDA has now approved Eli Lilly's new drug, Cymbalta, for treatment of depression. The new drug is expected to generate peak annual sales of about $2 billion, and is being described as a "much-needed boon for Eli Lilly after the sales of its former top-selling antidepressant Prozac fell due to generic competition." Let's take a closer look at the dynamics here. The big news being focused on in the mainstream media isn't that there is some new drug that can help people with depression -- the big news is that this is a new revenue generator for Eli Lilly. In the world of pharmaceuticals, it's always about profit and sales, and almost never about actually helping patients..."  
permalink